Canopy Growth's cannabis business is showing signs of a turnaround, with revenue growth, improving margins and a narrower EBITDA loss fueling its rally.

In the closing of the recent trading day, Tilray Brands, Inc. (TLRY) stood at $4.48, denoting a -4.07% move from the preceding trading day.

Aurora Cannabis faces a potential Curaleaf takeover at a 45% premium, but investors must weigh the offer against ACB's standalone prospects.

SNDL sinks after weak Q2 2026 earnings, but can cost cuts and U.S. expansion through Parallel offset ongoing cannabis and liquor headwinds?

Tilray Brands (TLRY) delivered earnings and revenue surprises of -2,050.00% and +9.14%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals pairs its FDA-approved CBD blockbuster with a diversified drug portfolio, offering medical cannabis exposure despite ongoing pipeline risks.

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.